Effective Component Compatibility of Bufei Yishen Formula III Which Regulates the Mucus Hypersecretion of COPD Rats via the miR-146a-5p/EGFR/MEK/ERK Pathway.

Jindi MaXuefang LiuYumeng WeiRuilong LuKexin XuYan-Ge Tian Jian-Sheng Li

Published in: Evidence-based complementary and alternative medicine : eCAM (2022)

ECC-BYF III has a significant effect in improving the airway mucus hypersecretion in COPD model rats, as well as a protective effect against limited pulmonary function and injured lung histopathology. The protective effect of ECC-BYF III in reducing airway mucus hypersecretion in COPD may involve the miR-146a-5p/EGFR/MEK/ERK pathway.

Keyphrases

chronic obstructive pulmonary disease
pi k akt
lung function
small cell lung cancer
signaling pathway
epidermal growth factor receptor
tyrosine kinase
cell proliferation
cystic fibrosis
air pollution